CTOs on the Move

RCSB Protein Data Bank

www.rcsb.org

 
The Protein Data Bank (PDB) was established as the 1st open access digital data resource in all of biology and medicine. It is today a leading global resource for experimental data central to scientific discovery.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

RCSB Protein Data Bank raised $34.5M on 11/04/2019

Similar Companies

Cradle Genomics

At Cradle Genomics, our mission is to provide knowledge that helps every pregnancy.

BioGenex Laboratories, Inc.

BioGenex Laboratories, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

MOMA Therapeutics

We`re on a mission to unlock molecular machines by understanding and respecting their complexities. We`ll be working incredibly hard to discover their untapped potential because we believe they are the key to delivering the next generation of precision medicines.

Kinnate

Kinnate Biopharma Inc. is a clinical-stage precision oncology company focused on expanding on the promise of targeted therapies for those battling cancer. The company is developing medicines for known oncogenic drivers where there are no approved targeted drugs and to overcome the limitations of marketed cancer therapies, such non-responsiveness or acquired and intrinsic resistance. Kinnate has two lead clinical programs being studied in solid tumors with RAF, NRAS and FGFR-driven alterations, and is rapidly progressing a pipeline of additional small molecule drug candidates as part of the Kinnate Discovery Engine.

Outlook Therapeutics

Oncobiologics, Inc. has changed its name to Outlook Therapeutics, Inc. Outlook Therapeutics is a clinical-stage biopharmaceutical company focused on developing its lead clinical program, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD). ONS-5010 is currently in its first clinical trial, which is being conducted outside of the U.S. and is designed to serve as the first of two adequate and well controlled studies for wet AMD.